Paradoxical thrombosis, part 2: Anticoagulant and antiplatelet therapy

Journal of Thrombosis and Thrombolysis

Volumn 34, Issue 3, 2012, Pages 367-373

  Lippi, Giuseppe ^a   Favaloro, Emmanuel J ^b   Franchini, Massimo ^c  

^a UNIVERSITY HOSPITAL OF PARMA   (Italy)

^b WESTMEAD HOSPITAL   (Australia)

^c CARLO POMA HOSPITAL   (Italy)

Author keywords

Anticoagulants; Antiplatelet agents; Atypical; Paradoxical; Pathogenesis; Thrombosis

Indexed keywords

ABCIXIMAB; ACENOCOUMAROL; ACETYLSALICYLIC ACID; ANTIBIOTIC AGENT; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; ANTIVITAMIN K; BRODIFACOUM; CLOPIDOGREL; COUMATETRALYL; DICOUMAROL; DIPYRIDAMOLE; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; ORBOFIBAN; PHENPROCOUMON; PLACEBO; QUININE; ROXIFIBAN; THIENOPYRIDINE DERIVATIVE; TICLOPIDINE; TIOCLOMAROL; TIROFIBAN; WARFARIN;

ACUTE CORONARY SYNDROME; ACUTE HEART INFARCTION; ARTERY THROMBOSIS; ARTICLE; BLEEDING DISORDER; BRAIN ISCHEMIA; BREAST NECROSIS; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; DRUG EFFICACY; DRUG FATALITY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; HEART ATRIUM FIBRILLATION; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; KIDNEY DYSFUNCTION; MORBIDITY; MULTIPLE ORGAN FAILURE; NEUROLOGIC DISEASE; NEUTROPENIA; PAIN; PARADOXICAL DRUG REACTION; PARADOXICAL THROMBOSIS; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PETECHIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SIDE EFFECT; SKIN NECROSIS; THROMBOCYTOPENIA; THROMBOEMBOLISM; THROMBOSIS; THROMBOTIC THROMBOCYTOPENIC PURPURA; VEIN THROMBOSIS; VENOUS THROMBOEMBOLISM; WEIGHT REDUCTION;

ANTICOAGULANTS; EMBOLISM, PARADOXICAL; HUMANS; PLATELET AGGREGATION INHIBITORS;

EID: 84868498340     PISSN: 09295305     EISSN: 1573742X     Source Type: Journal    
DOI: 10.1007/s11239-012-0748-0     Document Type: Article

References (59)

1. Lippi G, Franchini M, Targher G (2011) Arterial thrombus formation in cardiovascular disease. Nat Rev Cardiol 8:502-512
2. Lijfering WM, Flinterman LE, Vandenbroucke JP, Rosendaal FR, Cannegieter SC (2011) Relationship between venous and arterial thrombosis: a review of the literature from a causal perspective. Semin Thromb Hemost 37:885-896
3. Lippi G, Franchini M (2008) Pathogenesis of venous thromboembolism: when the cup runneth over. Semin Thromb Hemost 34:747-761
4. Lippi G, Favaloro EJ, Franchini M (2012) Paradoxical thrombosis part 1: factor replacement therapy, inherited clotting factor deficiencies and prolonged APTT. J Thromb Thrombolysis. doi:10.1007/s11239-012-0753-3
5. Lippi G, Franchini M, Favaloro EJ (2009) Unsuspected triggers of venous thromboembolism-trivial or not so trivial? Semin Thromb Hemost 35:597-604
6. Montagnana M, Favaloro EJ, Franchini M, Guidi GC, Lippi G (2010) The role of ethnicity, age and gender in venous thromboembolism. J Thromb Thrombolysis 29:489-496
7. Favaloro EJ, Franchini M, Lippi G (2011) Coagulopathies and thrombosis: usual and unusual causes and associations. Part V. Semin Thromb Hemost 37:859-862
8. Lehmeyer S, Lindhoff-Last E (2011) New aspects of paradoxical embolism. Vasa 40:31-40
9. The free dictionary. Definition of paradoxical. Available at: http://www.thefreedictionary.com/paradoxical
10. Tufano A, Coppola A, Cerbone AM, Ruosi C, Franchini M (2011) Preventing postsurgical venous thromboembolism: pharmacological approaches. Semin Thromb Hemost 37:252-266
11. Lippi G, Franchini M, Favaloro EJ (2009) Pharmacogenetics of vitamin K antagonists: useful or hype? Clin Chem Lab Med 47: 503-515
12. Palareti G, Legnani C (1996) Warfarin withdrawal. Pharmacokinetic- pharmacodynamic considerations. Clin Pharmacokinet 30: 300-313
13. Hirsh J, Fuster V, Ansell J, Halperin JL, American Heart Association; American College of Cardiology Foundation (2003) American Heart Association/American College of Cardiology Foundation guide to warfarin therapy. Circulation 107: 1692-1711
14. Flood EP, Redish MH, Bociek SJ, Shapiro S (1943) Thrombophlebitis migrans disseminate: report of a case in which gangrene of the breast occurred. N Y State Jr Med 43:1121-1124
15. Chan YC, Valenti D, Mansfield AO, Stansby G (2000) Warfarin induced skin necrosis. Br J Surg 87:266-272
16. McGehee WG, Klotz TA, Epstein DJ, Rapaport SI (1984) Coumarin necrosis associated with hereditary protein C deficiency. Ann Intern Med 101:59-60
17. Sallah S, Abdallah JM, Gagnon GA (1998) Recurrent warfarininduced skin necrosis in kindreds with protein S deficiency. Haemostasis 28:25-30
18. Oz BS, Asgun F, Oz K, Kuralay E, Tatar H (2007) Warfarininduced skin necrosis after open heart surgery due to protein S and C deficiency. Heart Vessels 22:64-66
19. Parsi K, Younger I, Gallo J (2003) Warfarin-induced skin necrosis associated with acquired protein C deficiency. Australas J Dermatol 44:57-61
20. Moreb J, Kitchens CS (1989) Acquired functional protein S deficiency, cerebral venous thrombosis, and coumarin skin necrosis in association with antiphospholipid syndrome: report of two cases. Am J Med 87:207-210
21. Malia RG, Kitchen S, Greaves M, Preston FE (1990) Inhibition of activated protein C and its cofactor protein S by antiphospholipid antibody. Br J Haematol 76:101-107
22. Makris M, Bardhan G, Preston FE (1996) Warfarin induced skin necrosis associated with activated protein C resistance. Thromb Haemost 75:523-524
23. Bhaijee F, Wainwright H, Meintjes G, Wilkinson RJ, Todd G, De Vries E, Pepper DJ (2010) Warfarin-induced skin necrosis in HIV-1-infected patients with tuberculosis and venous thrombosis. S Afr Med J 100:372-377
24. Ad-El DD, Meirovitz A, Weinberg A, Kogan L, Arieli D, Neuman A, Linton D (2000) Warfarin skin necrosis: local and systemic factors. Br J Plast Surg 53:624-626
25. Favaloro EJ, Lippi G, Koutts J (2011) Laboratory testing of anticoagulants - the present and the future. Pathology 43:682-692
26. Warkentin TE, Chong BH, Greinacher A (1998) Heparin-induced thrombocytopenia: towards consensus. Thromb Haemost 79:1-7
27. Linkins LA, Warkentin TE (2011) Heparin-induced thrombocytopenia: real-world issues. Semin Thromb Hemost 37:653-663
28. Martel N, Lee J, Wells PS (2005) Risk for heparin-induced thrombocytopenia with unfractionated and low molecular weight heparin thromboprophylaxis. Blood 106:2710-2715
29. Lassila R, Antovic JP, Armstrong E et al (2011) Practical viewpoints on the diagnosis and management of heparin-induced thrombocytopenia. Semin Thromb Hemost 37:328-336
30. Cuker A, Arepally G, Crowther MA et al (2010) The HIT Expert Probability (HEP) Score: a novel pre-test probability model for heparin induced thrombocytopenia based on broad expert opinion. J Thromb Haemost 8:2642-2650
31. Tan CW, Ward CM, Morel-Kopp MC (2012) Evaluating heparininduced thrombocytopenia: the old and the new. Semin Thromb Hemost 38:135-143
32. Prechel M, Walenga JM (2012) Heparin-induced thrombocytopenia: an update. Semin Thromb Hemost 38. doi: 10.1055/s-0032-1306432
33. Sheridan D, Carter C, Kelton JG (1986) A diagnostic test for heparin-induced thrombocytopenia. Blood 67:27-30
34. Warkentin TE, Kelton JG (1996) A 14-year study of heparininduced thrombocytopenia. Am J Med 101:502-507
35. Cuker A (2012) Current and emerging therapeutics for heparininduced thrombocytopenia. Semin Thromb Hemost 38:31-37
36. Lippi G, Favaloro EJ, Salvagno GL, Franchini M (2009) Laboratory assessment and perioperative management of patients on antiplatelet therapy: from the bench to the bedside. Clin Chim Acta 405:8-16
37. Biondi-Zoccai GG, Lotrionte M, Agostoni P et al (2006) A systematic review and meta-analysis on the hazards of discontinuing or not adhering to aspirin among 50,279 patients at risk for coronary artery disease. Eur Heart J 27:2667-2674
38. Doutremepuich C, Aguejouf O, Desplat V, Eizayaga FX (2010) Aspirin therapy: an attempt to explain the events of prothrombotic complications after treatment discontinuation. Thromb Haemost 103:171-180
39. Doutremepuich C, Aguejouf O, Desplat V, Eizayaga FX (2010) Paradoxical thrombotic effects of aspirin: experimental study on 1000 animals. Cardiovasc Hematol Disord: Drug Targets 10: 103-110
40. Cleland LG, James MJ, Stamp LK, Penglis PS (2001) COX-2 inhibition and thrombotic tendency: a need for surveillance. Med J Aust 175:214-217
41. Aster RH, Curtis BR, Bougie DW (2004) Thrombocytopenia resulting from sensitivity to GPIIb-IIIa inhibitors. Semin Thromb Hemost 30:569-577
42. Epelman S, Nair D, Downey R, Militello M, Askari AT (2006) Eptifibatide-induced thrombocytopenia and thrombosis. J Thromb Thrombolysis 22:151-154
43. Gao C, Boylan B, Bougie D et al (2009) Eptifibatide-induced thrombocytopenia and thrombosis in humans require FcgammaRIIa and the integrin beta3 cytoplasmic domain. J Clin Invest 119:504-511
44. Scirica BM, Cannon CP, Cooper R et al (2006) Drug-induced thrombocytopenia and thrombosis: evidence from patients receiving an oral glycoprotein IIb/IIIa inhibitor in the Orbofiban in Patients with Unstable coronary Syndromes (OPUS-TIMI 16) trial. J Thromb Thrombolysis 22:95-102
45. Bougie DW, Wilker PR, Wuitschick ED et al (2002) Acute thrombocytopenia after treatment with tirofiban or eptifibatide is associated with antibodies specific for ligand-occupied GPIIb/IIIa. Blood 100:2071-2076
46. Billheimer JT, Dicker IB, Wynn R et al (2002) Evidence that thrombocytopenia observed in humans treated with orally bioavailable glycoprotein IIb/IIIa antagonists is immune mediated. Blood 99:3540-3546
47. Merlini PA, Rossi M, Menozzi A et al (2004) Thrombocytopenia caused by abciximab or tirofiban and its association with clinical outcome in patients undergoing coronary stenting. Circulation 109:2203-2206
48. McClure MW, Berkowitz SD, Sparapani R et al (1999) Clinical significance of thrombocytopenia during a non-ST-elevation acute coronary syndrome. The platelet glycoprotein IIb/IIIa in unstable angina: receptor suppression using integrilin therapy (PURSUIT) trial experience. Circulation 99:2892-2900
49. Gao C, Boylan B, Bougie D et al (2009) Eptifibatide-induced thrombocytopenia and thrombosis in humans require FcgammaRIIa and the integrin beta3 cytoplasmic domain. Clin Invest 119:504-511
50. Aster RH (2005) Immune thrombocytopenia caused by glycoprotein IIb/IIIa inhibitors. Chest 127:53S-59S
51. Aster RH, Curtis BR, Bougie DW, Dunkley S, Greinacher A, Warkentin TE, Chong BH, on behalf of The Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis (2006) Thrombocytopenia associated with the use of GPIIb/IIIa inhibitors: position paper of the ISTH working group on thrombocytopenia and GPIIb/IIIa inhibitors. J Thromb Haemost 4:678-679
52. Linden MD, Tran H, Woods R, Tonkin A (2012) High platelet reactivity and antiplatelet therapy resistance. Semin Thromb Hemost 38:200-212
53. Bennett CL, Connors JM, Carwile JM et al (2000) Thrombotic thrombocytopenic purpura associated with clopidogrel. N Engl J Med 342:1773-1777
54. Lotta LA, Mancini I, Tuana G, Musallam KM, Peyvandi F (2012) Case report: use of thienopyridines in a patient with acquired idiopathic thrombotic thrombocytopenic purpura. J Thromb Thrombolysis
55. Zakarija A, Kwaan HC, Moake JL et al (2009) Ticlopidine- and clopidogrel-associated thrombotic thrombocytopenic purpura (TTP): review of clinical, laboratory, epidemiological, and pharmacovigilance findings (1989-2008). Kidney Int Suppl 112: S20-S24
56. Azarm T, Sohrabi A, Mohajer H, Azarm A (2011) Thrombotic thrombocytopenic purpura associated with clopidogrel: a case report and review of the literature. J Res Med Sci 16:353-357
57. Bennett CL, Kim B, Zakarija A et al; SERF-TTP Research Group (2007) Two mechanistic pathways for thienopyridine-associated thrombotic thrombocytopenic purpura: a report from the SERFTTP Research Group and the RADAR Project. J Am Coll Cardiol 50:1138-1143
58. von Mach MA, Eich A, Weilemann LS, Münzel T (2005) Subacute coronary stent thrombosis in a patient developing clopidogrel associated thrombotic thrombocytopenic purpura. Heart 91:e14
59. Oo TH (2006) Clopidogrel-associated thrombotic thrombocytopenic purpura presenting with coronary artery thrombosis. Am J Hematol 81:890-891